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OBJECTIVES: Common variable immunodeficiency (CVID) is associated with a spectrum of autoimmune
complications. We studied the prevalence of gastrointestinal (GI) manifestations and infections in
patients with CVID.
METHODS: Complete clinical data of 132Finnish patientswith CVID (106probable and26possibleCVID) followed
up between 2007 and 2016 were collected to a structured database. Data on endoscopies, histology,
and laboratory studies were retrieved from patient files.
RESULTS: Most common referral indications were diarrhea and/or weight loss (47%–67%). Patients with probable
CVID had higher fecal calprotectin and a1-antitrypsin and lower blood vitamin B12 than patients with
possible CVID. Gastroscopy and colonoscopy were done to 71 (67%) and 63 (59%) patients with
probable CVID, respectively. Endoscopies showed that 15% of them had chronic active gastritis and
17% atrophic gastritis and 3% had gastric adenocarcinoma. A celiac sprue-like condition was found in
7 patients (10%), of whom 3 responded to a gluten-free diet. Colonoscopies demonstrated unspecific
colitis (14%), ulcerative colitis (8%), microscopic colitis (10%), and Crohn’s disease (2%). Colonic
polyps were noted in 30%of patients, and3%had lower GImalignancies. Thirty-five patients with CVID
had bacterial or parasitic gastroenteritis; chronic norovirus was detected in 4 patients with probable
CVID. Patients with GI inflammation had higher levels of fecal calprotectin and blood CD81
T lymphocytes but lower counts of CD191CD271memory B cells and/or CD191 B cells.
Immunophenotype with low B-cell counts was associated with higher fecal calprotectin levels.
DISCUSSION: Patients with CVID had a high prevalence of GI manifestations and infections of the GI tract. GI
inflammation was associated with a distinct immunophenotype and elevated fecal calprotectin.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/A57
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INTRODUCTION
Common variable immunodeficiency (CVID) is the most com-
mon severely symptomatic primary immunodeficiency. Its
prevalence is 2–4 in 100,000 white population (1), whereas in
southern Finland, the CVID prevalence reaches 7.7 in 100,000
(2). CVID is a heterogeneous immunodeficiency disorder char-
acterized by a loss of B-cell function and impaired antibody
production (3). B-cell defects in CVID are frequently accompa-
nied by various immunologic changes, such as autoimmune
cytopenias, abnormal T-cell function, and polyclonal lympho-
proliferation (3). Patients with CVID are treated with immuno-
globulin (Ig) G infusions, which effectively reduce the risk of
infections (4) but have only a limited effect on additional com-
plications (3). Although newer criteria have been proposed,
CVID has traditionally been diagnosed using the European So-
ciety for Immunodeficiency/Pan-American Group for Immu-
nodeficiency criteria (2,5). These criteria define categories of
probable and possible CVID. Generally, in probable CVID, IgG
and IgA/IgM are decreased, whereas in possible CVID, only IgG
is decreased. Both diagnoses require impaired vaccine responses
and exclusion of secondary causes (5).
Previous studies have suggested a 9%–20% frequency of gas-
trointestinal (GI) disease in patients with CVID (6–8). Patients
with CVID typically have recurrent infections, but in addition,
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they may develop a wide range of autoimmune and auto-
inflammatory GI diseases (6). Importantly, the presence of GI
manifestations is a major risk factor for patients with CVID, with
a 2.7- to 4-fold increased mortality (6,7).
Therefore, to comprehensively analyze the GI phenotypes
associated with CVID and their prevalence, we assessed a Finnish
cohort of 132 patients with CVID who were followed up between
2007 and 2016. Our cohort was systematically screened for GI-
associated symptoms and findings by treating physicians. We
used readily available laboratory parameters to identify potential
screening tools for GI manifestations in this patient cohort and
assessed whether any B-cell immunophenotypes are associated
with gut inflammation.
MATERIALS AND METHODS
Patients
The study received local ethics consent (138/13/03/00/2013). All
adult patients receiving immunoglobulin replacement therapy
during the years 2007–2016who fulfilled the European Society for
Immunodeficiency/Pan-American Group for Immunodeficiency
criteria for primary CVID and the predetermined cutoff criteria
for impaired pneumococcal polysaccharide responses were
recruited (Table 1). Diagnostic criteria, immunophenotypes,
extragastrointestinal manifestations, and demographics of this
patient cohort have been described earlier in detail (2).
Laboratory parameters and histology
Laboratory tests were analyzed by the accredited HUSLAB (Hos-
pital District of Helsinki and Uusimaa Laboratory). Tests were or-
dered by the outpatient clinics of the Adult ImmunodeficiencyUnit
or the Department of Gastroenterology as a part of routine follow-
up. In addition, most of the 132 patients had additionally been
screened by the treating physicians for GI phenotype and malab-
sorption by measuring calprotectin (92%) and fecal a1-antitrypsin
(83%) as well as blood counts (100%) and vitamin B12 levels (79%).
Results assessed in this study include blood counts, serum vitamin
B12 and/or B12-TC2 (active B12 bound to transcobalamin II), flow
cytometry of lymphocytes (2), fecal markers (calprotectin and
a1-antitrypsin), and GI pathogens (see Supplementary Table 1,
Supplemental Digital Content 1, http://links.lww.com/AJG/A57).
Endoscopies and histology
Patients were referred for endoscopy mainly due to their symp-
toms and/or laboratory abnormalities (upper GI 92%, lower GI
94%; Figure 1). We analyzed all endoscopies performed for this
patient cohort (155 gastroscopies and 163 colonoscopies).
Overlap was noted, and altogether 71 patients had both endos-
copies (56 of them with probable CVID). Due to the lack of
biopsies or endoscopy reports, 6 gastroscopies and 8 colonos-
copies were excluded. Given the complexity of CVID-associated
GI manifestations, abnormal findings were reviewed by $2 ex-
pert pathologists and in a weekly joint clinical gastroenterology
and pathology meeting. Furthermore, upper GI histology of
patients with atrophic gastritis and/or duodenal pathology were
reanalyzed by an expert pathologist for Operative Link to Gas-
tritis Assessment (OLGA) classification or Corazza-Villanacci
classification, respectively (see Supplementary Tables 2a and 2b,
SupplementalDigital Content 1, http://links.lww.com/AJG/A57).
All patients with mucosal inflammation had at least two separate
endoscopy examinations.
Bile acid malabsorption
Bile acid malabsorption was assessed by giving 10 mCi (370 kBq)
of selenium75-labeled taurine salt capsule (SeHCAT-test) with
a lactose-free meal. Measurements were done by g-camera 3
hours and 7 days after ingestion of the capsule. For normal bile
acid absorption, over 10% of activity was needed to be detectable
still at day 7; activity below 10% of the baseline was considered as
bile acid malabsorption.
Table 1. Demographics of a cohort of 132 patients with CVID
Demographic Probable CVID Possible CVID
No. of patients 106 26
Age (yr) 516 16 546 17
Male 50 (47%)* 8 (33%)
CVID Dg (yr) 20046 9.7 2010 6 2.4
IgG (6.8–15 g/L) 2.36 1.64** 5.81 6 2.36
IgA (0.08–1.4 g/L) 0.17 6 0.20** 0.89 6 0.70
IgM (0.47–2.84 g/L) 0.32 6 0.61** 0.76 6 0.47
P-IgE (0–110 g/L) 4.56 6 8.61** 35.5 6 86.73
B-cell phenotype
B2 16 (15%) 1 (4%)
smB2 56 (54%)** 3 (12%)
21low 45 (44%)** 5 (20%)
smB-21low 32 (31%)* 1 (15%)
CVID, common variable immunodeficiency.
The year of CVID diagnosis, age, and the average plasma concentrations of
immunoglobulins (6SD when applicable) are shown. Reference range of each
immunoglobulin class is in the parenthesis. For B-cell phenotypes, the following
abbreviations were used: B25 CD191B cells#1% of lymphocytes, smB25
switched memory B cells #2% of B cells, 21low5 CD21low cells $10% of B
cells. In total, 129 patients with CVID had B-cell phenotyping data available. For
statistical comparisons between patients with probable and possible CVID,
Mann-Whitney U test was used. *P, 0.05; **P, 0.001.
Figure 1. Flowchart of patients with CVID. CVID, common variable im-
munodeficiency; 75SeHCAT, selenium75-labeled taurine salt absorption
measurement for bile acid malabsorption.
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Data collection and analysis
A comprehensive and structured computer database (Microsoft
Access; Microsoft Corporation, Redmond, WA) was generated for
the input of the medical history, immunophenotype, endoscopy,
histology, and retrospective patient data (2). Microsoft Excel
(Microsoft Corporation, Redmond, WA) and SPSS Statistics 22.0
(IBM, Armonk, NY) and Prism 7 (GraphPad, San Diego, CA) were
used for the analyses. Any frequencies, including GI diseases and
aberrant laboratory parameters, were studied using descriptive sta-
tistics and crosstabs functions. For comparisons of variables between
groups, Mann-Whitney U-test or Fisher’s exact test was used, as
appropriate. P, 0.05 was considered significant.
RESULTS
Patient population
The patient cohort consisted of 106 patients with probable CVID
and26with possibleCVID (Table 1). Thereweremoremale patients
amongpatientswithprobableCVIDthanamong thosewithpossible
CVID (47% vs 33%; P , 0.05). Patients with probable CVID had
been diagnosed earlier (average year: 2004 vs 2010; P , 0.001).
Chronic anemia was detected in 47 patients (35.6%), of whom 39
(83%) had undergone gastroscopy and 35 (74%) colonoscopy. In
comparisons between patients with probable and possible CVID,
more patients with probable CVID had decreased vitamin B12
levels (28.6% vs 5.3%; P , 0.05); fecal calprotectin and a1-
antitrypsin levels were significantly higher in patients with prob-
ableCVID (Figure 2). The defect of B-cell function in patientswith
CVID makes detection and interpretation of autoantibodies dif-
ficult: We did not find IgA autoantibodies in patients with IgA
deficiency, and barely detectable levels of IgG autoantibodies may
be artificially from gammaglobulin supplementation.
GI endoscopy and histology
Upper GI. Gastroscopy findings are presented in Table 2 (prob-
able and possible CVID in separate columns). The findings are
presented as a proportion of all 90 patients with CVID (mainly
reflecting findings from patients with probable CVID).
Esophagus. Typical endoscopic and histologic findings of gas-
troesophageal reflux disease (GERD) or Candida albicans
esophagitis were found altogether in 9%of patients (Table 2). One
patient had esophageal inflammatory ulcerations due to Crohn’s
disease. A single Barrett esophagus without dysplasia was found.
Stomach.Chronic active or atrophic gastritis was themost common
upperGI finding, infrequently linked toHelicobacter pylori infection
(Table 2). Parietal cell antibodies were not detected even in patients
with corpus-restricted atrophic gastritis without H. pylori infection
(autoimmune gastritis), and hence biopsies are necessary in patients
with CVID. Two patients had a history of Helicobacter-negative
chronic gastritis that had progressed to gastric atrophy when gastric
adenocarcinoma was found. Classification of atrophic gastritis his-
tology is presented in Supplementary Table 2a (see Supplemental
Digital Content 1, http://links.lww.com/AJG/A57).
Duodenum and small bowel. Duodenal villous blunting and in-
creased intraepithelial lymphocytes (IELs) were found in 9% of
patients (Table 2), and histologic classification is presented in
Supplementary Table 2b (see Supplemental Digital Content 1,
http://links.lww.com/AJG/A57). One patient with possible CVID
had IgG autoantibodies against tissue transglutaminase and had the
human leukocyte antigen (HLA)-DQ2 haplotype. This patient ex-
perienced a complete response to gluten-free diet (GFD). Another
patient was on GFD based on celiac disease diagnosis 40 years
Figure 2. Fecal markers of patients with possible and probable CVID.
(a) Fecal calprotectin levels in patients with probable CVID (n5 96, white
bar) and in patients with possible CVID (n5 25, black bar). (b) Fecal a1-
antitrypsin levels in patients with probable CVID (n5 96, white bar) and in
patients with possible CVID (n5 19, black bar). Upper limits of laboratory
reference ranges are marked with a dotted line: for fecal calprotectin 100
mg/g and for fecal a1-antitrypsin 268mg/g. Results are shown for each bar
(a and b) as average6 SEM. For statistical comparison between patients
with possible and probable CVID, Mann-Whitney U test was used. **P,
0.0001; *P, 0.05. CVID, common variable immunodeficiency.
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earlier (before CVID diagnosis) and had no villous atrophy albeit
demonstrated increased IEL. The third patient had detectable anti-
endomycial IgG antibodies (on gammaglobulin supplementation)
andwas also positive forHLA-DQ2haplotype. Hewas refractory to
GFD and was a chronic norovirus carrier (discussed later). Two
patients had no celiac autoantibodies but still got a normalization of
villous atrophy after GFD while an increase in IEL persisted.
Patients who did not respond to GFD (n 5 4) neither had anti-
enterocyte IgG antibodies and aberrant lymphocyte infiltrates
(duodenal biopsy) nor had T-cell receptor rearrangement detected.
However, HLAhaplotypewas not systemically screened, and only 4
patients from the whole cohort were tested. Two patients withGFD
unresponsive enteropathy had HLA-DQ8 or -DQ2 haplotype but
were also chronic norovirus carriers. The remaining 2 patients not
responding to GFD had extensive inflammation also elsewhere in
the GI tract. One of them had “graft-vs-host”-like colitis, and the
other had esophagitis, colitis, and chronic gastritis progressing to
gastric adenocarcinoma. In addition, 3 patients had ileal in-
flammatory lesions. One patient was operated for an inflammatory
(nongranulomatous, and likely of ischemic etiology) stricture of
proximal ileumand remained asymptomatic. The other patient had
ileocolonic and perianal Crohn’s disease, and a third had unspecific
luminal ileocolonic inflammation. Whereas terminal ileum was
endoscopically investigated and biopsied in 91% of lower GI
endoscopies, a small bowel capsule endoscopy was additionally
performed on 7 patients, and only 1 patient with probable CVID
had an endoscopic finding, an extensive nodular lymphatic hy-
perplasia throughout the small bowel.
Lower GI. Of patients with CVID, 76 had a colonoscopy with
available biopsies and endoscopy report. Findings were divided
into possible and probable CVID groups (Table 2) but presented
as a proportion of all patients (mainly reflecting patients with
probable CVID). Table 3 describes the histologic inflammatory
changes in the lower GI tract.
Colon. Microscopic colitis, i.e., collagenous or lymphocytic co-
litis, was found in 9% of patients (Table 2). However, an un-
specific colitis related to CVID was additionally found in 14% of
the patients. Inflammatory bowel disease (IBD) was diagnosed in
8% of patients, consisting predominantly of ulcerative colitis.
Two patients with ulcerative colitis were refractory to treatment
and underwent colectomy.One patient with unspecific colitis and
nodular lymphatic hyperplasia of the gut developed cecal large
B-cell lymphoma; another elderly patient was diagnosed with
a metastatic colon adenocarcinoma. The most frequent finding
was follicular lymphatic hyperplasia (41%), followed by lym-
phocytosis of the mucosa (30%) and intraepithelial neutrophils
(20%) (Table 3). In addition, cryptitis (9%) and/or crypt abscesses
(12%) were relatively common. Interestingly, all patients with
duodenal inflammation had also colonic inflammation.
Bile acid malabsorption
Ten patients with unexplained diarrhea were tested for bile acid
absorption, and malabsorption was found in 4 (40%) of the
tested patients, all of them with probable CVID. One of the
patients had previous ileocolic and anastomose resections due to
stricturing Crohn’s disease, whereas the others were type II bile
acid malabsorption.
GI infections
GI infections were mainly found in patients with probable CVID
(Figure 3), whereas altogether 35 patients with CVID had at least
Table 2. GI findings of patients with CVID
Probable
CVID
Possible
CVID
Upper GI endoscopy
No. of patients 71 19
Esophagus
Candida esophagitis 3 (4%) 1 (5%)
Reflux esophagitis 3 (4%) 1 (5%)
Esophageal ulceration 2 (3%) 0
Barret esophagus 1 (1%) 0
Stomach
Chronic gastritis 11 (15%) 1 (5%)
Gastritis with H. Pylori 2 (3%) 1 (5%)
Atrophic gastritis 12 (17%) 1 (5%)
Atrophic gastritis with H. Pylori 0 1 (5%)
Benign polyps 3 (4%) 1 (5%)
Benign lymphatic proliferation and
gastrectomy
1 (1%) 0
Gastric carcinoma 2 (3%) 0
Small bowel
Enteropathy (villous blunting and
increased IEL)
7 (10%) 1 (5%)
GFD response 3 (4%) 1 (5%)
Nodular lymphatic hyperplasia 3 (4%) 0
Inflammatory stricture (ileum) 2 (3%) 0
Lower GI endoscopy
No. of patients 63 13
Colon
Colitis ulcerosa 5 (8%) 0
Colectomy 2 (3%) 0
Crohn’s disease 1 (2%) 0
Unspecific ileocolitis 1 (2%) 0
Radiation proctitis (after cervical
cancer)
1 (2%) 0
Collagenous colitis 1 (2%) 0
Lymphocytic colitis 5 (8%) 0
Unspecific colitis (related to CVID) 9 (14%) 2 (15%)
CMV colitis (colectomy) 1 (2%) 0
HSV colitis 1 (2%) 0
Malignancy of colon 2 (3%) 0
Benign polyp 19 (30%) 4 (31%)
CMV, cytomegalovirus; CVID, common variable immunodeficiency; GFD,
gluten-free diet; GI, gastrointestinal; HSV, Herpes simplex virus; IEL,
intraepithelial lymphocyte.
The upper GI endoscopy with biopsies was done at least once to 71 and 19 patients
with probable and possible CVID, respectively. Colonoscopy with biopsies was done
at least once to 63 and 13 patients with probable and possible CVID, respectively.
There were no statistical differences between patients with probable and possible
CVID (Fisher’s exact test). Total count of findings is followed by the proportion (%) of
findings among the endoscopically examined patients.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology The American Journal of GASTROENTEROLOGY
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once a bacterial or parasitic gastroenteritis. Of all patients with
CVID, 5% had eitherGiardia lamblia orDientamoeba fragilis.H.
pylori was found in 8 of the tested 107 patients with CVID.
Successful eradication was confirmed by negative fecal Heli-
cobacter antigen or gastric biopsy staining. Seventy-eight patients
were tested with fecal bacterial culture and of those 31 addi-
tionally with polymerase chain reaction (PCR). In concordance
with previous studies (3,9,10), Campylobacter, Salmonella and
Yersinia species, andClostridiumdifficilewere found (concordant
results with bacterial culture and PCR). Only by PCR, we detected
2 pathogenic strains of Escherichia coli, enteroaggregative
(EAEC) and enteropathogenic (EPEC), in 13% of patients with
probable CVID. Themost common viral infectionwas norovirus,
which was found in 7% of patients (n 5 9). Four patients
remained chronic carriers of norovirus. Except for the norovirus,
GI infections were not detected concomitantly in patients with
colonic inflammation. Patients recovered from theirGI infections
and had no endoscopy at the time.
Risk factors of GI inflammation
Fecal markers. Fecal calprotectin and a1-antritrypsin were used
as screening tools before GI endoscopy, and in fact, the patients
who had no lower GI endoscopy performed (n5 50) had also low
fecal markers (fecal calprotectin 58 6 68 mg/g and fecal a1-
antritrypsin 2276 148 mg/g [average6 SD; n5 43 and n5 40,
respectively]). To avoid bias in the analyses, we excluded patients
without endoscopic examinations. We combined histologic signs
of chronic lower GI inflammation (lymphocytosis, cryptitis, and/
or crypt abscesses). Patients with inflammatory GI histology had
elevated (.95% confidence interval) fecal calprotectin levels
(mg/g)—212.6–994.4 with inflammation (n 5 26) vs 69.1–312.0
without inflammation (n 5 50) (P , 0.05; Figure 4a)—but not
of a1-antitrypsin (Figure 4b).
Immunophenotype.We investigated the flow cytometry findings
of peripheral blood lymphocytes in patients with CVID in re-
lation to lower GI inflammation. In patients with lower GI in-
flammation, the proportion of CD191 B cells of all lymphocytes
was lower, but the proportion of CD31 T cells of all lymphocytes
was higher (Figure 4c). In particular, CD191CD271 memory
B cells were reduced among CD191 B cells and CD81
T lymphocytes were higher among CD31 T cells (Figure 4c).
Furthermore, whereas we compared bowel inflammation mark-
ers and B-cell counts among all patients of the cohort (in-
dependent of endoscopies), we found that the subgroup of
patients having a very low amount of CD191 B lymphocytes
(,2% of all lymphocytes; B2) had elevated fecal calprotectin
levels (Figure 4d) but not of fecal a1-antitrypsin (data not
shown).
DISCUSSION
We describe here that in systematically evaluated patients with
CVID, various inflammatory and infectious GI diseases are
frequent. In total, 70% and 64% of our patients with CVID
Table 3. Lower GI inflammation in patients with CVID
Histology Probable CVID Possible CVID
Follicular lymphatic hyperplasia 31 (49%) 0
Increased lymphocytes 23 (37%) 2 (15%)
Increased neutrophils 15 (24%) 1 (8%)
Cryptitis 10 (16%) 0
Crypt abscess 7 (11%) 0
Crypt distortion 9 (14%) 0
Ileitis 3 (5%) 0
Apoptotic activity 1 (2%) 0
CVID, common variable immunodeficiency; GI, gastrointestinal.
The histologic findings of ileocolonoscopy are reported both as a total count of
findings and a proportion (%) of findings among the patients endoscopically
examined (n5 63 in probable CVID and n513 in possible CVID). Asmarkers of
chronic inflammation, we selected lymphocytosis, cryptitis, and/or crypt
abscesses, and used their combination in the further analyses in respect to
other biomarkers.
Figure 3.Gastrointestinal infections in patients with CVID. Numbers of patients with GI infection and causing pathogens are shownwith bars. We only show
the number of patients who have had one or more infections by a pathogen, whereas the numbers of recurrent infections are not shown. Black bars mark
probable CVID and white bars mark possible CVID. CVID, common variable immunodeficiency; CMV, cytomegalovirus; EAEC, enteroaggregative E. coli;
EPEC, enteropathogenic E. coli; HSV, Herpes simplex virus.
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underwent upper and lower GI endoscopy, respectively. In
addition, 92% were screened for fecal calprotectin and 87% for
fecal antitrypsin. Among patients without a colonoscopy, 86%
and 80% were screened with fecal calprotectin and a1-
antritrypsin, respectively. Moreover, endoscopic and/or his-
tologic abnormalities were detected in 58% and 68% of upper
and lower GI endoscopy, respectively. To the best of our
knowledge, this CVID cohort has the highest proportion of
patients evaluated with endoscopy and markers for enteric
inflammation in the available literature. We also describe bile
acid malabsorption and infections by enteropathogenic strains
of E. coli and D. fragilis as frequent causes of treatable diarrhea
in patients with CVID. However, this study may have inherent
sources of bias given the observational setting. Bias might arise
from a patient’s preference to bring samples or undergo en-
doscopy as well as the clinician’s selection of investigations.
Contrarily, if the total patient cohort was limited only to
symptomatic patients with CVID with both endoscopies done,
this might further bias the detected prevalence.
Endoscopy-positive GERD was found in 4% of patients. This
prevalence is less than that in the general Finnish population,
where endoscopy-positive GERD was found in 9.8% of patients
(11). A plausible explanation may be that atrophic gastritis is
often found in patients with CVID. This may have a protective
effect against GERD (11). The prevalence of esophageal mani-
festations in patients with CVID has previously been largely
unknown, whereas our study suggests for the first time that
endoscopy-positive GERD may be less common in patients with
CVID than in the general population.
In a previous retrospective case series, 26 of 30 upper GI
endoscopies demonstrated chronic gastritis in biopsies, and H.
pyloriwas found in 8 (27%) (9). In the present study,H. pyloriwas
screened from 81% (107) of patients. H. pylori was relatively
uncommon (6%), and the incidence of chronic active gastritis was
also lower (12%). Similarly, in a recently published Norwegian
CVID cohort, only 3 (6%) H. pylori infections were found in 50
upper GI endoscopies. However, in the present study, atrophic
gastritis was found similarly or more frequently than in other
CVID cohorts (6,12–14). We found atrophic gastritis in 17% of
upper GI endoscopies, whereas the prevalence of atrophic gas-
tritis has varied between 3% and 9% in the large cohorts of
patients with CVID (6,12); but these may underestimate its
prevalence because in smaller cohorts atrophic gastritis was
found in 10%–20% of gastric biopsies of patients with CVID
(13,14). In the present cohort, 2 gastric cancers were in 106
patients with probable CVID during 10 years; this 1.8% preva-
lence of gastric carcinoma is twice as high as that altogether 4
gastric cancers in 472 patients (0.8%) in published large cohorts
(15,16). Thus, patients with CVID are at higher risk of stomach
cancer, and therefore, a screening gastroscopy is justified and
likely a follow-up endoscopy if chronic active gastritis or atrophic
gastritis is detected.
CVID enteropathy is associated with higher mortality (6).
CVID enteropathy is histologically like that of celiac disease
with villous atrophy, crypt hyperplasia, and increased IEL.
Distinctive features often include a paucity of plasma cells and
unresponsiveness to GFD (17,18). However, we found that half
of the patients with CVID enteropathy responded to GFD.
Notably, the patients who did not respond to GFD were either
carriers of norovirus or had extensive inflammation in the GI
tract. CVID enteropathy has been linked to chronic norovirus
carriage, and its clearance was associated with the resolution of
symptoms and histologic recovery of villous atrophy (19).
In the present study, 2 patients with chronic norovirus had
GFD refractory enteropathy and malnutrition due to protein-
losing diarrhea. In contrast, 2 other chronic norovirus carriers
had only occasional GI symptoms, without any duodenal
inflammation. In addition to norovirus carriage, other patho-
gens including Salmonella and EAEC were detected in these
patients, suggesting that they may be more susceptible to GI
infections in general. Therefore, whether these persistent GI
infections are the cause or effect in the context of CVID en-
teropathy requires further study. Moreover, future inves-
tigations on genetic factors predisposing patients with CVID to
GI inflammation are warranted.
We found thatGI inflammation in patients withCVID ismore
common in the lower GI tract than in the upper GI tract. Mi-
croscopic colitis and unspecific colitis linked to CVID were
common findings and found in altogether 23% of colonoscopies.
IBD was diagnosed in 11% of patients who were endoscopically
Figure 4. Inflammation of the colon, fecal markers, and immunopheno-
type. (a) Patients without histologic inflammation in colon biopsies (n550)
had lower fecal calprotectin levels than patients with inflammation (n 5
24). (b) Patients without histologic inflammation in the colon (n5 45) had
no difference in fecal a1-antitrypsin levels compared with patients with
histologic inflammation (n 5 23). (c) Peripheral blood proportions of
CD191CD271 memory B cells of CD191 B cells (black bars) and
CD31CD81 T lymphocytes of CD31 Tcells (white bars) in patients with or
without inflammation in the colon. Histologic inflammation is indicated in
the graphs with 2 (n5 54) and1 (n5 25) signs below x axis. (d) Fecal
calprotectin was higher in the subgroup of patients with a very low amount
of CD191B lymphocytes (,2%of all lymphocytes; B2; n514) than in the
rest of patientswithCVID (B1; n5107). The results are shown for eachbar
(a–d) as average6 SEM. For statistical comparison between patients with
possible and probable CVID, Mann-Whitney U test was used. *P, 0.05.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology The American Journal of GASTROENTEROLOGY
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examined. The 5% IBD prevalence in the whole cohort was over
5-fold higher than in the Finnish general population (20). Fecal
calprotectin was elevated in patients with colonic inflammation.
Consequently, we suggest that fecal calprotectin may serve as
a screening tool for GI inflammation in patients with CVID,
before endoscopy. Importantly, we report here for the first time
that patients with CVID with unexplained diarrhea had a high
frequency (40%) of bile acid malabsorption. Bile acid malab-
sorption should be excluded in the workup of chronic diarrhea of
a patient with CVID.
Historical reports suggest G. lamblia as the most common
cause of gastroenteritis in patients with CVID (21). However, we
found altogether 20 patients with bacterial GI infections caused
by Salmonella, Campylobacter, Yersinia, or C. difficile, and only 6
parasitic infections caused by G. lamblia or D. fragilis (Figure 3).
In addition, a total of 14 positive samples for nucleic acids of
EAEC or EPEC were found in patients with gastroenteritis,
whereas 10 patients had viral pathogens including norovirus,
cytomegalovirus, or Herpes simplex virus. In Iranian patients
with CVID, 86 of 115 patients had GI infections during 30 years
(22). Furthermore, of 248 patients with CVID from the United
States, 6 had bacterial GI infections (Salmonella, Campylobacter)
and 8 G. lamblia infections (16). Giardiasis was thus found less
frequently in Finnish patients with CVID, whereas Salmonella
and Campylobacter infections were similarly common. In addi-
tion, the prevalence of D. fragilis and of pathogenic strains of E.
coli was similar or higher than that of previously described
pathogens in patients with CVID. Given the high incidence of GI
infections in them, screening of fecal pathogens is warranted in
the initial evaluation of persistent diarrhea and whenever there is
an exacerbation of chronic GI symptoms.
In line with a French cohort of 50 patients with CVID (9), we
found that patients with CVID with a higher proportion of pe-
ripheral blood CD81 lymphocytes had also more intestinal in-
flammation. In this previous study (9), intestinal lymphocytosis
was largely due to the expansion of CD81 lymphocytes. In ad-
dition, we found that peripheral blood B-cell and memory B-cell
proportions were lower in patients with intestinal inflammation.
A subgroup of patients with CVID with a very low B-cell count
had elevated fecal calprotectin levels, suggesting that very low
B-cell counts may be a risk factor for intestinal inflammation.
This corroborates previous findings that higher levels of peripheral
blood B cells may protect against noninfectious complications of
CVID (8).
In conclusion, patients with CVID frequently have GI
comorbidity. Infection or inflammation of the GI tract is the
main cause. In total, more than 50% of all gastroscopies lead to
a diagnosis, ranging from chronic inflammation to gastric
cancer. The high incidence of GI infections in patients with
CVID warrants the screening of pathogens before endoscopic
examinations. Colonic inflammation appears to be more prev-
alent than upper GI inflammation, yet when present, duodenal
inflammation predicts also lower GI inflammation. Fecal cal-
protectin may help in the screening of these patients for GI
inflammation, like in IBD. Gut inflammation was associated
with a distinct immunophenotype with lower blood counts of
B cells and memory B cells but increased counts of CD81
T lymphocytes. Therefore, readily available laboratory param-
eters such as fecal calprotectin and distinct immunophenotype
may help to stratify individual risk of GI manifestations in
patients with CVID.
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